NCT07434180尚未招募2 期
Phase II Trial of Lu-177 FAP-2286 in Patients With Carcinoma of Unknown Primary
Peter MacCallum Cancer Centre, Australia1 个研究点 分布在 1 个国家目标入组 20 人开始时间: 2026年6月1日最近更新:
干预措施
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 20
- 试验地点
- 1
- 主要终点
- Overall Response Rate (ORR)
研究概览
简要总结
The aim of the study is to test if a new radionuclide therapy, called 177-Lu-FAP-2286, works to treat cancer in patients with Cancer of Unknown Primary (CUP).
详细描述
The aim of the Lu-FAP-CUP trial is to assess preliminary efficacy signal of 177Lu-FAP-2286 in CUP patients with 68Ga-FAPI-46 positive disease.
This is a prospective, open label, single site, phase II clinical trial designed to evaluate the safety and efficacy of 177Lu-FAP-2286 monotherapy in CUP patients.
Patients who meet all eligibility criteria will be registered into the trial and receive up to 6 cycles of 177Lu-FAP-2286 monotherapy every 28 days.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients must meet all the following criteria for trial entry:
- •Patient has provided written informed consent
- •Patients aged 18 years or over at Screening
- •Diagnosed with CUP based on a diagnostic work-up, including, but not limited to; a detailed clinical assessment; a CT CAP; pathological review of tumour tissue; and other appropriate tests as per the Cancer Council Optimal Care Pathway guidelines.
- •Progressed on 1st line platinum doublet chemotherapy +/- immunotherapy +/- antibody therapy
- •68Ga-FAPI-46 positive disease on 68Ga-FAPI-46-PET/CT defined as 68Ga-FAPI-46 uptake at PET/CT with SUVmax of ≥ 8 in at least 50% of target lesions and above surrounding background in the remaining target lesions
- •Eastern Cooperative Oncology Group (ECOG) performance status 0-2 (Appendix 1).
- •Life expectancy greater than 3 months
- •Adequate bone marrow, hepatic and renal function defined by the following laboratory results:
- •Haemoglobin ≥ 90 g/L independent of transfusion (no red blood cell transfusion within 4 weeks before the haematology Screening assessment)
- •Absolute neutrophil count ≥ 1.5 x 109/L
- •Platelet count ≥ 100 x 109/L
- •Creatinine clearance (CrCl) ≥ 60 mL/min calculated using the Cockcroft-Gault equation (Appendix 2)
- •Serum bilirubin ≤ 1.5 x upper limit of normal (ULN); Patients with known Gilbert's disease may have a bilirubin ≥ 3.0 x ULN
- •Aspartate transaminase (AST) or alanine transaminase (ALT) ≤ 2 x ULN (or ≤ 5 x ULN in the presence of liver metastases)
- •Have measurable disease per RECIST1.1 (Appendix 3)
- •Sexually active Patients are willing to use medically acceptable forms of barrier contraception as outlined in Section 8.1.5.1, during treatment and for 6 months following the last dose of treatment
- •Women of childbearing potential (WCBP) must have a negative serum pregnancy test result
- •Willing to undergo biopsies if disease is considered accessible and biopsy is feasible
- •Willing and able to comply with all trial requirements, including all treatment and required assessments and follow-up procedures, in the Investigator's judgment
排除标准
- •Patients who meet any of the following criteria will be excluded from trial entry:
- •Uncontrolled medical or psychological conditions that may prevent commencement of systemic treatment
- •Symptomatic and/or untreated central nervous system metastases or leptomeningeal disease. Patients must be clinically stable for at least 4 weeks without steroid treatment
- •Surgical procedure (minor surgery ≤ 5 days, or major surgery ≤ 21 days) prior to registration or active infection requiring systemic treatment Note: Placement of vascular access devices, laparoscopy and prophylactic procedures to stabilise bone lesions are not considered major surgical procedures
- •Received anticancer treatment ≤ 14 days prior to registration (≤ 28 days prior in case of checkpoint inhibitor or other antibody therapies)
- •Severe impaired cardiac function (left ventricular ejection fraction < 35%) or clinically significant uncontrolled cardiac disease
- •Severe urinary incontinence, voiding dysfunction, or unrelieved urinary obstruction
- •Ongoing AEs from anticancer treatment > Grade 1 as per CTCAE v5.0, with the exception of alopecia
- •Received prior radiopharmaceutical therapy or radioembolisation, or prior extensive external beam radiation therapy (EBRT) to bone marrow or any prior EBRT directly to kidney or received any EBRT within 2 weeks prior to registration
- •Concurrent illness, including severe infection that may jeopardise the ability of the patient to undergo procedures outlined in this protocol with reasonable safety
- •Prior cancer diagnosis with the exception of:
- •Malignancy treated with curative intent and with no known active disease ≥ 3 years and of low potential risk of recurrence
- •Adequately treated basal cell or squamous cell skin carcinoma or non-invasive melanoma
- •Adequately treated non-muscle invasive bladder cancer (Tis, Ta and low grade T1 tumours)
- •Adequately treated carcinoma in situ without evidence of disease
- •Cancer patients with incidental histologic findings of prostate cancer that, in the opinion of the Investigator, is not deemed to require active therapy (e.g., incidental prostate cancer identified following cystoprostatectomy that is tumour/node/metastasis stage ≤ pT2N0)
- •Greater than one prior line of systemic treatment
- •Known allergy or reaction to 18F, 68Ga or 177Lu radiopharmaceuticals
- •Concurrent illness, including severe infection that may jeopardise the ability of the patient to undergo the procedures outlined in the protocol with reasonable safety
研究组 & 干预措施
177Lu-FAP-2286
Experimental
In this single arm study, patients with CUP will receive up to 6 cycles of 177Lu-FAP-2286 monotherapy every 28 days.
干预措施: 177Lu-FAP-2286 (Drug)
结局指标
主要结局
Overall Response Rate (ORR)
时间窗: From start of treatment until end of follow-up (study completion- 2 years after the last patient has commenced treatment)
ORR is defined as complete response (CR) or partial response (PR) as per RECIST1.1 at any time after commencement of treatment.
次要结局
- Progression Free Survival (PFS)(start of treatment until end of follow-up period (study completion- 2 years after the last patient has commenced treatment) or death/withdrawal of patient consent)
- Evaluation of Safety(From the start of treatment until the 6-week post treatment safety follow-up visit)
- PERCIST response(From screening till 12 weeks after commencing treatment)
研究者
研究点 (1)
Loading locations...
相似试验
招募中
2 期
Radiometabolic Therapy (RMT) with 177Lu PSMA in PSMA PET/CT positive advanced/metastatic tumours: a basket trial (LUBASKET)2024-519346-75-00Istituto Romagnolo Per Lo Studio Dei Tumori Dino Amadori IRST S.r.l.83
招募中
1/2 期
DUET-study: A FEASIBILITY STUDY OF 177LU-PSMA RADIOLIGAND THERAPY ALTERNATED WITH RADIUM-223 IN PATIENTS WITH BONE-METASTATIC, OLIGO-METASTATIC HORMONE-SENSITIVE PROSTATE CANCER AFTER CURATIVE THERAPY.Prostate cancer2024-518985-29-02Amsterdam UMC Stichting, Bayer B.V.6
尚未招募
1 期
A Phase I/II Study to Evaluate XNW34017 in Patients With Advanced or Metastatic Solid TumorNCT07327294Evopoint Biosciences Inc.150
已完成
2 期
A phase I study of [177Lu]Lu-FF58 in patients with advanced solid tumors2022-502367-37-00Novartis Pharma AG55
已完成
1 期
A Study to Learn if a Medicine That Reduces Stomach Acid Affects the Blood Level of Study Medicine PF-08049820 in Healthy Chinese Adults.NCT07284173Pfizer18